Exscientia
Exscientia - Model EXS21546 - Peripherally-Restricted and Selective Antagonist Drug
FromExscientia
EXS21546 is our peripherally-restricted and selective antagonist of the Adenosine A2a Receptor. It is designed for anti-cancer immunotherapy, combatting adenosine related immunosuppressive effects, through T-cell activation.
Most popular related searches
whole blood sample
T-cell
cancer cell
whole blood
blood sampling
cancer immunotherapy
clinical trial
cancer treatment
patient blood
cancerous tumor
To interrogate signaling and disease-relevant endpoints, prior to the Phase 1 clinical trial of EXS21546.
We analysed ex vivo activity in patient-derived whole blood samples and primary cancer cells from viable pancreas and lung tissue.
This study demonstrated potential for EXS21546 in cancer therapy, reducing tumour cell burden while inducing an expansion of the viable CD8+ T cell fraction.
EXS21546 is undergoing first-in-human studies (NCT04727138)